David Kirn Sells 15,725 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $12.03, for a total value of $189,171.75. Following the completion of the sale, the insider directly owned 884,152 shares in the company, valued at approximately $10,636,348.56. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Kirn also recently made the following trade(s):

• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total value of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Stock Down 0.2%

Shares of FDMT opened at $11.68 on Thursday. 4D Molecular Therapeutics, Inc. has a twelve month low of $4.14 and a twelve month high of $14.00. The stock has a market capitalization of $610.58 million, a P/E ratio of -4.54 and a beta of 2.70. The company has a 50 day moving average of $10.33 and a 200-day moving average of $9.41.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. boosted its stake in shares of 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after acquiring an additional 1,050 shares during the period. Martingale Asset Management L P increased its holdings in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after acquiring an additional 1,303 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after acquiring an additional 2,069 shares during the period. Russell Investments Group Ltd. raised its stake in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after acquiring an additional 2,284 shares during the period. Finally, Prelude Capital Management LLC lifted its holdings in 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after purchasing an additional 2,300 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

FDMT has been the topic of several analyst reports. Chardan Capital reissued a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.